Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial
Authors' conclusion
The use of 1,700 mg/day MET is effective to prevent diabetes in people selected on the basis of metabolic syndrome.
Study context
- Population
- People with metabolic syndrome
- Participants
- 1,442 people
- Comparison
- Metformin (MET) with or without Mediterranean diet (MedDiet) vs placebo
- Primary endpoint
- Cumulative incidence of major noncommunicable diseases (incl. T2D, CVD and cancer)
- Follow-up
- Mean 3 years
Methodological detailsfactorial, placebo-controlled
- Factorial
- Placebo-controlled
Primary result
As reported in the abstract
Crude incidence of major noncommunicable diseases
MET+MedDiet
6.7 cases per 100 person-years
MET alone
6.9
cases per 100 person-years
Placebo plus MedDiet
13.3
cases per 100 person-years
Placebo
11.3
cases per 100 person-years
Secondary outcomes
Incidence of T2D
- T2D lower with MET alone vs placebo
- 80%
- T2D lower with MET+MedDiet vs placebo
- 92%
Original publication
Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial. Diabetes Care. Published 6 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →